Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.

International journal of molecular sciences - 18 Apr 2018

Itatani Yoshiro, Kawada Kenji, Yamamoto Takamasa, Sakai Yoshiharu

Abstract excerpt

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Phenotype

Share to Signal Transduction

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 29670046
DOI: 10.3390/ijms19041232
PMCID: PMC5979390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.PMID 29670046Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.Semantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells.Semantic proximity Read ↗

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomasSemantic proximity Read ↗

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read ↗

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.Semantic proximity Read ↗

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant CancersSemantic proximity Read ↗

The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular RemodelingSemantic proximity Read ↗

Functions of the VEGF/VEGF Receptor System in the Vascular SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.